230 related articles for article (PubMed ID: 33876897)
1. Management of women with uterine fibroids in reproductive center: retrospective analysis of clinical and reproductive outcomes.
Miriello D; Galanti F; Meneghini C; Fabiani C; Dal Lago A; Schiavi MC; Rago R
Minerva Obstet Gynecol; 2022 Apr; 74(2):130-136. PubMed ID: 33876897
[TBL] [Abstract][Full Text] [Related]
2. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Morgante G; Centini G; Troìa L; Orvieto R; De Leo V
Reprod Biol Endocrinol; 2020 May; 18(1):50. PubMed ID: 32430027
[TBL] [Abstract][Full Text] [Related]
3. The management of uterine fibroids in women with otherwise unexplained infertility.
Carranza-Mamane B; Havelock J; Hemmings R; ;
J Obstet Gynaecol Can; 2015 Mar; 37(3):277-285. PubMed ID: 26001875
[TBL] [Abstract][Full Text] [Related]
4. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
5. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
6. Ulipristal acetate prior to in vitro fertilization in a female patient affected by uterine fibroids: a case report.
Lo Monte G; Piva I; Graziano A; Engl B; Marci R
Eur Rev Med Pharmacol Sci; 2016; 20(2):202-7. PubMed ID: 26875885
[TBL] [Abstract][Full Text] [Related]
7. Impact of subserosal and intramural uterine fibroids that do not distort the endometrial cavity on the outcome of in vitro fertilization-intracytoplasmic sperm injection.
Oliveira FG; Abdelmassih VG; Diamond MP; Dozortsev D; Melo NR; Abdelmassih R
Fertil Steril; 2004 Mar; 81(3):582-7. PubMed ID: 15037406
[TBL] [Abstract][Full Text] [Related]
8. Fibroid management in premenopausal women.
Donnez J; Courtoy GE; Dolmans MM
Climacteric; 2019 Feb; 22(1):27-33. PubMed ID: 30601065
[TBL] [Abstract][Full Text] [Related]
9. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
10. Fibroids that do not distort the uterine cavity and IVF success rates: an observational study using extensive matching criteria.
Christopoulos G; Vlismas A; Salim R; Islam R; Trew G; Lavery S
BJOG; 2017 Mar; 124(4):615-621. PubMed ID: 27921379
[TBL] [Abstract][Full Text] [Related]
11. Measurement of changes in uterine and fibroid volume during treatment of heavy menstrual bleeding (HMB).
Yin K; Whitaker L; Hojo E; McLenachan S; Walker J; McKillop G; Stubbs C; Priest L; Cruz M; Roberts N; Critchley H
Hum Reprod Open; 2023; 2023(3):hoad021. PubMed ID: 37304815
[TBL] [Abstract][Full Text] [Related]
12. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
13. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
14. The effect of ≤6 cm sized noncavity-distorting intramural fibroids on in vitro fertilization outcomes: a systematic review and meta-analysis.
Erden M; Uyanik E; Polat M; Ozbek IY; Yarali H; Mumusoglu S
Fertil Steril; 2023 Jun; 119(6):996-1007. PubMed ID: 36813123
[TBL] [Abstract][Full Text] [Related]
15. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
16. Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study.
Czuczwar P; Wozniak S; Szkodziak P; Milart P; Wozniakowska E; Wrona W; Paszkowski T
Ultrasound Obstet Gynecol; 2015 Jun; 45(6):744-50. PubMed ID: 25251811
[TBL] [Abstract][Full Text] [Related]
17. Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
Giarrè G; Franchini M; Castellacci E; Malune ME; Di Spiezio Sardo A; Saccone G; Angioni S
Gynecol Endocrinol; 2020 Feb; 36(2):171-174. PubMed ID: 31392917
[TBL] [Abstract][Full Text] [Related]
18. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
19. Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study.
Netter A; Pauly V; Siles P; Pivano A; Vidal V; Agostini A
Reprod Biomed Online; 2019 Nov; 39(5):795-801. PubMed ID: 31594689
[TBL] [Abstract][Full Text] [Related]
20. Effects of myomas and myomectomy on assisted reproductive technology outcomes.
Fortin CN; Hur C; Radeva M; Falcone T
J Gynecol Obstet Hum Reprod; 2019 Nov; 48(9):751-755. PubMed ID: 31077869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
